ATC Group: J04AB04 Rifabutin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04AB04 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J04 Antimycobacterials
3 J04A Drugs for treatment of tuberculosis
4 J04AB Antibiotics
5 J04AB04 Rifabutin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.15 g

Active ingredients in J04AB04

Active Ingredient Description
Rifabutin

Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex.

Related product monographs

Title Information Source Document Type  
MYCOBUTIN Capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.